| Literature DB >> 9564630 |
J Sterling1, A Veinberg, D Lerner, W Goldenberg, R Levy, M Youdim, J Finberg.
Abstract
(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson's Disease. This compound is currently under development for that indication.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9564630 DOI: 10.1007/978-3-7091-6499-0_30
Source DB: PubMed Journal: J Neural Transm Suppl ISSN: 0303-6995